360° UPSC Mains Analysis

Manila, Philippines

The Philippines lies along the tectonically active Pacific Ring of Fire, making it highly prone to volcanic eruptions and earthquakes, and is frequently hit by typhoons due to its tropical maritime climate. India's geography is dominated by the southwest and northeast monsoon systems, while its northern boundary is shaped by the tectonically active Himalayan collision zone.

The bilateral meeting took place in Manila, Philippines, an archipelagic nation in Southeast Asia situated in the western Pacific Ocean. The discussions emphasized the Indo-Pacific region, which connects the Indian and Pacific Oceans through critical maritime chokepoints like the Strait of Malacca, Sunda Strait, and Lombok Strait.

The Indo-Pacific region is a vital global trade route carrying over half of the world's maritime trade and energy shipments. The bilateral talks highlighted critical minerals, which are geographically concentrated but essential for high-tech manufacturing, green energy transition, and artificial intelligence infrastructure.

Under the Seventh Schedule of the Constitution, foreign trade and international relations fall exclusively under the Union List (List I). Specifically, Entry 10 (Foreign affairs), Entry 14 (Entering into treaties and agreements), and Entry 41 (Trade and commerce with foreign countries) empower the Union Government to negotiate and implement the interim trade deal and manage tariffs, ensuring a unified national policy.

The US is India's largest pharmaceutical export destination, accounting for USD 9.74 billion (37.7%) of India's total USD 25.8 billion pharma exports in 2025. Indian companies supply approximately 47% of all generic prescriptions dispensed in the US. The interim trade deal aims to address tariff disparities, but the impending 100% to 200% US tariffs on generics by 2028 will force India to aggressively expand its trade footprint in Europe, Africa, and Latin America.

The proposed US tariff hike on generic drugs (100% in 2028, rising to 200% thereafter) poses a medium-term risk to India's current account balance, as the US is India's largest pharma export market, importing USD 9.74 billion in 2025. While the immediate 2-year zero-tariff window prevents near-term shocks to India's forex reserves, the eventual tariff escalation could widen the trade deficit and pressure the Rupee. However, the finalization of the interim trade deal and key defense agreements could offset these losses by boosting bilateral trade and investment flows.

The secondary sector, specifically the pharmaceutical industry, faces a bifurcated outlook: near-term stability followed by severe medium-term headwinds for generic drug manufacturers. Higher-value generic formulations and branded generics will face intense pressure to onshore or diversify, while low-cost generics may absorb some tariff shocks due to their extreme cost-competitiveness. Conversely, the defense and critical minerals sectors are poised for growth through finalized bilateral agreements, enhancing domestic manufacturing capabilities.

The pharmaceutical manufacturing supply chain in India, which employs over 2.5 million people directly and indirectly, could face wage stagnation or job losses post-2028 if export volumes to the US contract. To mitigate this, domestic manufacturers may accelerate supply chain diversification toward alternative markets in Europe, Latin America, and Africa. In the short term, the 2-year tariff holiday ensures stable employment and production levels across major pharma hubs like Maharashtra, Gujarat, and Andhra Pradesh.

Post-independence, India-US relations were shaped by Cold War geopolitics, with India pursuing non-alignment and the US aligning with Pakistan. Bilateral trade was limited and transactional, exemplified by the PL-480 program under the US Agricultural Trade Development and Assistance Act of 1954, which highlighted India's food dependency and the political leverage the US held. This strategic divergence prevented any deep trade or defense agreements for decades, establishing a legacy of cautious bilateral engagement.

The economic liberalization of 1991 marked a shift, leading to the 'Next Steps in Strategic Partnership' (NSSP) in 2004. The landmark 123 Agreement (Civil Nuclear Deal) in 2008 fundamentally altered the strategic trajectory, leading to India being designated a 'Major Defense Partner' in 2016. In recent years, the relationship has transitioned to a 'Comprehensive Global Strategic Partnership' with a focus on critical technologies (iCET launched in 2023) and resilient supply chains, despite persistent tariff disputes.

The current tension between strategic alignment (Indo-Pacific, defense) and trade friction (tariffs on generics) parallels the late 1980s and early 1990s. During that period, while the US and India began cooperating on space and high-tech, trade disputes under the Special 301 provisions of the US Trade Act of 1974 over India's intellectual property laws and pharmaceutical patents created significant bilateral friction.

The freedom struggle's emphasis on 'Swadeshi' (self-reliance) and economic sovereignty, championed by leaders like Mahatma Gandhi during the Swadeshi Movement of 1905, continues to influence India's cautious approach to free trade agreements (FTAs) and its defense of domestic industries against foreign tariff pressures.

The extraction of critical minerals, a key focus of the India-US partnership, poses severe threats to fragile ecosystems and biodiversity-rich regions, leading to habitat fragmentation, soil erosion, and heavy metal contamination of water bodies. Additionally, the potential shift or expansion in pharmaceutical manufacturing (generic drugs) can exacerbate chemical pollution in aquatic ecosystems, releasing Active Pharmaceutical Ingredients (APIs) that disrupt local food webs.

The underlying science involves the chemical synthesis of Active Pharmaceutical Ingredients (APIs) and the development of advanced extraction and refining technologies for critical minerals. Additionally, the integration of Artificial Intelligence (AI) in material science helps optimize the discovery of alternative materials and improves the efficiency of mineral processing, while biotechnology is utilized in bioremediation to clean up pharmaceutical effluents.

Critical minerals are essential for manufacturing clean energy technologies like electric vehicle (EV) batteries, solar panels, and wind turbines, which are vital for India to meet its Nationally Determined Contributions (NDCs) under the Paris Agreement, including achieving 500 GW of non-fossil fuel capacity by 2030. However, the mining and processing of these minerals are highly carbon-intensive, presenting a sustainability paradox where the materials needed for decarbonization contribute to global greenhouse gas emissions.

The bilateral cooperation directly impacts SDG 7 (Affordable and Clean Energy) and SDG 13 (Climate Action) through clean energy and critical mineral supply chains. It also links to SDG 12 (Responsible Consumption and Production) by highlighting the need for sustainable mining practices under the Mines and Minerals (Development and Regulation) Amendment Act, 2023, and the sound management of pharmaceutical waste under India's National Action Plan for Antimicrobial Resistance (NAP-AMR), 2017, aligning with Article 48A (Directive Principles) and Article 51A(g) (Fundamental Duties) of the Constitution of India.

The tariff hike directly threatens the livelihoods of lakhs of workers employed in India's pharmaceutical manufacturing, R&D, and supply chain sectors. On a global scale, it restricts access to affordable, life-saving generic medicines, directly compromising the right to health and dignity for millions of low-income patients who depend on cheap Indian exports.

Under Article 21 of the Indian Constitution, the Right to Life includes the Right to Health and access to affordable medical treatment, as affirmed by the Supreme Court in State of Punjab v. Ram Lubhaya Bagga (1998). Furthermore, Article 47 (DPSP) mandates the State to improve public health, while Article 12 of the International Covenant on Economic, Social and Cultural Rights (ICESCR) recognizes the right to the highest attainable standard of physical and mental health, including access to essential medicines.

As a District Magistrate of a major pharmaceutical manufacturing hub (such as Solan or Hyderabad), the primary ethical conflict would be balancing local economic stability and employment preservation against strict compliance with changing international trade standards. There is also a tension between prioritizing immediate welfare support for laid-off pharma workers versus long-term structural skilling for industrial transition.

The proposed US tariff hike on generic medicines could severely impact the livelihoods of thousands of workers, particularly women who constitute a significant portion of the packaging and assembly workforce in India's pharmaceutical sector. Additionally, any domestic price adjustments by pharma companies to offset export losses could disproportionately affect the Economically Weaker Sections (EWS) and elderly who rely heavily on affordable generic healthcare.